Vivani Medical Inc. has published a presentation outlining its progress and strategy in the obesity and chronic disease treatment market. The company is developing NPM-139, a miniature, subdermal semaglutide implant designed for chronic weight management in obese and overweight individuals. Unlike currently approved GLP-1 therapies, which are available only as injectables or orals, Vivani's NanoPortal technology enables dosing every 6 to 12 months via a subdermal implant. The company reports that its LIBERATE-1 first-in-human study achieved its primary objectives, demonstrating positive safety, tolerability, and device performance. Vivani projects that its cash runway will extend through key milestones and into 2027, with the NPM-139 clinical program set to begin in the first half of 2026. The presentation also notes the growing GLP-1 market, which is expected to reach $139 billion by 2030. You can access the full presentation through the link below.